Hair loss is not listed as a known or direct adverse effect in the FDA prescribing information for Ozempic (semaglutide) or Wegovy (semaglutide for weight management)
Melnik BC, Schmitz G (2013) Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1
While individual patterns vary based on personal fat distribution and receptor density, users commonly report improvements in areas that had not responded adequately to diet and exercise alone
Take home message The STEP 9 trial showed that Wegovy 2.4 mg taken alongside lifestyle support for 68 weeks reduced knee pain and improved physical function in adults living with knee osteoarthritis and obesity, with an average weight loss of 13.7%
Source: The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor AgonistOnce-Weekly Semaglutide and the FLOW Trial Results Symposium
The key outcome measures were GSH levels in various body compartments, including blood, erythrocytes, plasma, lymphocytes, and exfoliated buccal mucosal cells